Professor Colin Baigent
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial
- ATT: Antithrombotic Trialists' Collaboration
- Coxib and traditional NSAID (CNT) Collaboration
- CTT: Cholesterol Treatment Trialists' Collaboration
- EMPA-KIDNEY: the study of heart and kidney protection with empagliflozin
- Gastroprotectant Trialists' (GPT) Collaboration
- MTT: Marfan Treatment Trialists' Collaboration
- Renal Studies Group
- Research Regulation
- SHARP: Study of Heart and Renal Protection
- STT: Stroke Thrombolysis Trialists' Collaboration
- Trials Methodology
- UK HARP III
- Anaemic heart failure: factors associated with progression from severe morbidity to death among pregnant women in India
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU)
- Individual patient meta-analyses of randomized trials of aspirin for the primary prevention of cardiovascular disease (MRC PHRU)
- Medical Research Council Population Health Research Unit (MRC PHRU)
Professor of Epidemiology and Director, MRC PHRU
- Deputy Director, CTSU
Colin Baigent studied Medicine at Bristol and Oxford University (1983-89), having originally studied Mathematics at Oxford (1980-83).
He became an MRC career scientist in 2002, and in 2006 was appointed Professor of Epidemiology at Oxford. From July 2013, he became Deputy Director of CTSU.
His main interest is in cardiovascular epidemiology, and most particularly the design, conduct and application of large-scale randomised trials in cardiovascular disease. His research includes the coordination of meta-analyses of randomised trials, typically with individual participant data, resulting in landmark papers that have helped determine the effects of aspirin (and other antiplatelet drugs), non-steroidal anti-inflammatory drugs, fibrinolytic therapy, and statins in different types of patients. His group has also contributed to a better understanding of cardiovascular disease in patients with renal impairment through the Study of Heart and Renal Protection (SHARP), the largest ever in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries.
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK
Zhou J. et al, (2022), PharmacoEconomics
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology
Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.
Gaziano L. et al, (2022), Circulation